To include your compound in the COVID-19 Resource Center, submit it here.

Chugai sales and marketing update

Chugai launched Alecensa alectinib in Japan to treat unresectable, recurrent or advanced anaplastic

Read the full 133 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE